Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue

Conclusion
Armodafinil 150 mg/day was well tolerated in primary brain tumor patients undergoing RT with good compliance. While there was no overall significant effect on fatigue, those with greater baseline fatigue experienced improved QOL and reduced fatigue when using armodafinil. These data suggest that a prospective, phase III randomized trial is warranted for patients with greater baseline fatigue.

Source: Neuro-Oncology - September 22, 2015 Category: Cancer & Oncology Authors: Page, B. R., Shaw, E. G., Lu, L., Bryant, D., Grisell, D., Lesser, G. J., Monitto, D. C., Naughton, M. J., Rapp, S. R., Savona, S. R., Shah, S., Case, D., Chan, M. D. Tags: Clinical Investigations Source Type: research